148 related articles for article (PubMed ID: 2129413)
21. Rapid dissociation of platelet-rich fibrin clots in vitro by a combination of plasminogen activators and antiplatelet agents.
Lam SC; Dieter JP; Strebel LC; Taylor TM; Muscolino G; Feinberg H; Le Breton GC
J Pharmacol Exp Ther; 1991 Dec; 259(3):1371-8. PubMed ID: 1762085
[TBL] [Abstract][Full Text] [Related]
22. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
Sabovic M; Lijnen HR; Keber D; Collen D
Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
[TBL] [Abstract][Full Text] [Related]
23. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
24. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
25. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
26. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
27. Differential fibrinolytic properties of the recombinant plasminogen activator BM 06.022 in human plasma and blood clot systems in vitro.
Martin U; Sponer G; Strein K
Blood Coagul Fibrinolysis; 1993 Apr; 4(2):235-42. PubMed ID: 8388740
[TBL] [Abstract][Full Text] [Related]
28. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
[TBL] [Abstract][Full Text] [Related]
29. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
[TBL] [Abstract][Full Text] [Related]
30. "Plasminogen steal" and clot lysis.
Torr SR; Nachowiak DA; Fujii S; Sobel BE
J Am Coll Cardiol; 1992 Apr; 19(5):1085-90. PubMed ID: 1532403
[TBL] [Abstract][Full Text] [Related]
31. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
32. Protein C and fibrinolysis: a link between coagulation and fibrinolysis.
de Fouw NJ; Haverkate F; Bertina RM
Adv Exp Med Biol; 1990; 281():235-43. PubMed ID: 2102614
[TBL] [Abstract][Full Text] [Related]
33. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets.
Prager NA; Torr-Brown SR; Sobel BE; Abendschein DR
J Am Coll Cardiol; 1993 Jul; 22(1):296-301. PubMed ID: 8509554
[TBL] [Abstract][Full Text] [Related]
34. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
35. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
36. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
37. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis.
Tomczyk M; Suzuki Y; Sano H; Brzoska T; Tanaka H; Urano T
Thromb Res; 2016 Jul; 143():28-33. PubMed ID: 27179129
[TBL] [Abstract][Full Text] [Related]
38. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
Gurewich V; Pannell R
Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
[TBL] [Abstract][Full Text] [Related]
39. Changes in clot lysis levels of reteplase and streptokinase following continuous wave ultrasound exposure, at ultrasound intensities following attenuation from the skull bone.
Härdig BM; Carlson J; Roijer A
BMC Cardiovasc Disord; 2008 Aug; 8():19. PubMed ID: 18727834
[TBL] [Abstract][Full Text] [Related]
40. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo.
Mittermayr M; Streif W; Haas T; Fries D; Velik-Salchner C; Klingler A; Innerhofer P
Br J Anaesth; 2008 Mar; 100(3):307-14. PubMed ID: 18158312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
